API | teprotumumab

teprotumumab (Tepezza) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA First in Class Fast Track ^FDA Breakthrough Therapy ^FDA

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
teprotumumab

More Chemistry

Pharmacology

Mechanisms of Action:
- IGF-like family receptor 1 (Homo sapiens) ^UniProt
- Insulin-like growth factor 1 receptor (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$11380.9000 - $14900.0000

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

r1507 | r 1507 | r-1507 | r-1507 monoclonal antibody | rg1507 | rg 1507 | rg-1507 | rg-1507 monoclonal antibody | ro-4858696 | ro-4858696000 | teprotumumab

Organizations (9)

Research & Development (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (1)

Graves Ophthalmopathy (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Graves Ophthalmopathy (Phase 4)

Macular Edema (Phase 1)

Neoplasms (Phase 1)

Sarcoma (Phase 2)

Scleroderma, Diffuse (Phase 1)

Thyroid Gland (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 17
# of Trial Organizations: 9

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue